RALEIGH-DURHAM-CHAPEL HILL AREA, NC, UNITED STATES, January 10, 2025 /EINPresswire / -- Xraised, the <a target=_blank href= ...

The continued investment in this clinical portfolio of services will allow Champions to better serve its clients by offering increased depth through higher complexity spectral analysis. Champions is ...

A simple prototype cell sorter has grown over time to incorporate technological advances that make it an even more indispensable tool for understanding biology and disease states ...

Plasmacytoid dendritic cells (pDC) primarily function as weak antigen-presenting cells (APC), but have also been shown to ...

BioSkryb Genomics, a pioneer in single-cell and ultra-low input multiomics is excited to announce the launch of ResolveSEQ MRD, an innovative service offering designed to empower further ...

HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to annou ...

Rapid advances in automation are improving every step of the flow cytometry process, from sample preparation to data analysis. Laboratories that adopt and implement these tools will be able to ...

In a report released yesterday, Mark Massaro from BTIG maintained a Buy rating on NeoGenomics (NEO – Research Report), with a price target of ...

The course covers the basic principles and applications, as well as experimental design and advanced high-parameter flow cytometry. During the course the students will get training in hands-on data ...

The course covers the basic principles and applications, as well as experimental design and advanced high-parameter flow cytometry. During the course the students will get training in hands-on data ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.